sB7-H3 as a prognostic biomarker in osteosarcoma: Insights into clinical outcomes
Presenter: Yuwei Zhao, MS Session: Prognostic Biomarkers 2 Time: 4/20/2026 2:00:00 PM → 4/20/2026 5:00:00 PM
Authors
Lu Xie 1 , Yuwei Zhao 1 , Kunkun Sun 2 , Yiyang Yu 1 , Jie Xu 1 , Yuhang Wang 1 , Chenchen Yang 1 , Hengyue Ma 1 , Tingting Ren 1 , Xiaodong Tang 1 1 Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China, 2 Pathology Department, Peking University People’s Hospital., Beijing, China
Abstract
B7 homolog 3 protein (B7-H3), a member of the B7 checkpoint family, is aberrantly and consistently expressed on the membranes of various human cancer cells and is associated with poor prognosis. Emerging evidence also indicates that soluble B7-H3 (sB7-H3) correlates with adverse outcomes in multiple malignancies. In this study, we measured sB7-H3 levels in peripheral blood using an enzyme-linked immunosorbent assay (ELISA) from 100 newly diagnosed osteosarcoma (OTS) patients, both before and after neoadjuvant chemotherapy, and simultaneously assessed B7-H3 tissue expression via immunohistochemistry (IHC) analysis of surgical specimens. Our analysis showed significant associations between B7-H3 tissue expression and histopathological response to chemotherapy, with the H-score threshold >75 identifying patients with particularly poor prognosis ( p p p < 0.05). These findings highlight serum sB7-H3 as a clinically valuable biomarker in OTS, providing prognostic information both at diagnosis and throughout the course of treatment in a relatively convenient manner.
Disclosure
L. Xie, None.. Y. Zhao, None.. K. Sun, None.. Y. Yu, None.. J. Xu, None.. Y. Wang, None.. C. Yang, None.. H. Ma, None.. T. Ren, None.. X. Tang, None.
Cited in
Control: 248 · Presentation Id: 10109 · Meeting 21436